MedPath

Efficacy of Helicobacter pylori eradication followed by sequential administration of proton pump inhibitor and proton pump inhibitor plus prokinetic for the patients with dyspepsia

Not Applicable
Conditions
patients with dyspepsia and H.pylori infection
Registration Number
JPRN-UMIN000012827
Lead Sponsor
Okayama University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
200
Inclusion Criteria

Not provided

Exclusion Criteria

1) patients with past history of gastrectomy 2) patients with alarm symptom auch as vomiting, gastrointestinal hemorrhage, and rapid body weight loss 3) reflux esophagitis (> and = Los Angeles grade A) or peptic ulcer 4) patients with the following diseases or previous history: Zollinger-Ellison syndrome; inflammatory bowel disease; esophageal stenosis; Achalasia; and organic disease in the brain 5) severe diseases in liver, kidney, and heart 6) persons with malignancy or possibility of malignancy 7) expect muther, mother with breast-feeding 8) under administration of atazanavir sulfate 9) drug allegy for penicillin 10) administration the following drugs within 2 weeks: proton pump inhibitors; histamine 2-receptor antagonists; and prokinetics 11) other not applicable person recognized by a doctor

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1) overall evaluation for each treatment by patients 2) evaluation of symptom index (modified F scale) at baseline, post 4 weeks treatment of rabeprazole, and post 4 weeks treatment of rabeprazole plus acotiamide
Secondary Outcome Measures
NameTimeMethod
1) assessment of the symptom factors that influence the efficacy during the treatment from the symptom index (modified F scale) 2) patients'QOL by using SF 8 scale at baseline, post 4 weeks treatment of rabeprazole, and post 4 weeks treatment of rabeprazole plus acotiamide
© Copyright 2025. All Rights Reserved by MedPath